Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance of Metformin Treated Women With PCOS
NCT ID: NCT02683226
Last Updated: 2016-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
30 participants
INTERVENTIONAL
2015-03-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin
NCT01911468
Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome
NCT02483299
Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome
NCT03566225
Spironolactone Plus Metformin in Polycystic Ovary Syndrome
NCT01526616
Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome
NCT06142656
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
metformin and alogliptin
Vipdomet 12.5 mg/1000 mg tablets
Vipdomet
pioglitasone and alogliptin
Incresync 12,5 mg/30 mg tablets
Incresync
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vipdomet
Incresync
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* polycystic ovary syndrome (NICHD criteria)
* BMI of 30 kg/m² or higher
Exclusion Criteria
* history of carcinoma
* Cushing's syndrome or congenital (non-classic) adrenal hyperplasia
* personal or family history of MEN 2
* significant cardiovascular, kidney or hepatic disease
18 Years
55 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrej Janez
Andrej Janez, MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Center Ljubljana
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MTT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.